Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
Completed · Phase 2 · Has a placebo group
Conditions studied: Schizophrenia
In brief
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
Key facts
- Study ID
- NCT00487942
- Run by
- Cephalon
- People needed
- 60
- Starts
- 2007-07-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2013-07-19
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative NeuroScience Network — Garden Grove, California, United States
- Synergy Clinical Research — National City, California, United States
- California Clinical Trials — Paramount, California, United States
- CNRI-Los Angeles, LLC — Pico Rivera, California, United States
- CNRI-San Diego — San Diego, California, United States
- Yale University School of Medicine — New Haven, Connecticut, United States
- Atlanta Center for Clinical Research — Atlanta, Georgia, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Duke Department of Psychiatry - DUMC — Durham, North Carolina, United States
- Midwest Clinical Research Center — Dayton, Ohio, United States
- University Hills Clinical Research — Irving, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.